GlobeNewsWire
16 Nov 2026, 12:50 UTC · 12h ago
Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
Impact · against what's priced in
Allarity Therapeutics' expansion of its Stenoparib Phase 2 trial suggests positive early momentum and a broader potential addressable market in ovarian cancer. This serves as a modest growth catalyst by increasing the scope of the clinical validation process.
Scored by the NIS engine · methodology.

Search tags




